Purpose To evaluate the efficacy and safety of erlotinib in advanced non-small-cell lung
cancer after failure of gefitinib treatment. Patients and methods Patients with advanced or …

Aims and background: Erlotinib approval was supported by the positive results of a large
multicentric phase III trial (BR. 21 study) that included 10% Asiatic patients and the …

7504 Background: Poor performance status (PS) NSCLC is an important, under-studied
group of lung cancer patients, affecting 30-40% of patients. We determined the role of …

Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …

7625 Background: In advanced NSCLC, E and B either as a single agent (E) or in
combination with chemotherapy (B) show improved survival. Combinations of targeted …

Purpose: This multicenter, phase II study evaluates the efficacy and safety of erlotinib, an
epidermal growth factor receptor (EGFR) inhibitor, plus sorafenib, a multityrosine kinase …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

Learning Objectives After completing this course, the reader will be able to: Describe the
molecular mechanism of action of erlotinib. Define clinical and molecular predictors of …

Introduction Currently, the inhibitor of the epidermal growth factor receptor tyrosine kinase
erlotinib is widely used for the treatment of non-small cell lung cancer. Patients with a …

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …